Showing results (1911-1920 of 2,013) with videos related to

Sort By:
Pageof 202
Annals of Surgery|January 20, 2015
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancerCristina R Ferrone, Giovanni Marchegiani, Theodore S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment ResponseToni T Seppälä, Jacquelyn W Zimmerman, Reecha Suri, et al.
Carcinogenesis|June 25, 2015
Disruptive chemicals, senescence and immortalityAmancio Carnero, Carmen Blanco-Aparicio, Hiroshi Kondoh, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2018
Epigenetic alterations in longevity regulators, reduced life span, and exacerbated aging-related pathology in old father offspring miceKan Xie, Devon P Ryan, Brandon L Pearson, et al.
Nature Cancer|February 5, 2022
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterationsPriscilla K Brastianos, Albert E Kim, Nancy Wang, et al.
JACC. Cardiooncology|October 31, 2024
Multicohort Epigenome-Wide Association Study of All-Cause Cardiovascular Disease and Cancer Incidence: A Cardio-Oncology ApproachArce Domingo-Relloso, Angela L Riffo-Campos, Naisi Zhao, et al.
JCO Precision Oncology|July 12, 2021
Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal CancerSusan G R McDuff, Karin M Hardiman, Peter J Ulintz, et al.
Nature Medicine|January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
Carcinogenesis|May 24, 2015
Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactionsJulia Kravchenko, Emanuela Corsini, Marc A Williams, et al.
British Journal of Cancer|June 25, 2014
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancerA F Hezel, M S Noel, J N Allen, et al.
Pageof 202